ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

9 links1 made here, not in the record11 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older versionMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06802757Posaconazole Plus PD-1Inhibitors and Chemotherapyvs PD-1 Inhibitors andChemotherapy in NeoadjuvantTherapy for Triple NegativeBreast CancerShandong Cancer Hospital and IPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 4 · ClinicalTrials.gov record · Version of 2026-11-04Nov 4 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSBreast NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Triple Negative Breast Neop…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSPosaconazoleIntervention entry›Nov 18 · Rule based · TestedTestedAlbumin-Bound PaclitaxelEntry “Nab-paclitaxel”, read by our n…›Nov 18 · Rule based · BackgroundBackgroundCarboplatinIntervention entry›Nov 18 · Rule based · BackgroundBackgroundAnthracyclinesEntry “Anthracycline”, read by our na…›Nov 18 · Rule based · BackgroundBackgroundCyclophosphamideIntervention entry›Nov 18 · Rule based · BackgroundBackgroundImmune checkpoint inhibitorsEntry “PD-1 inhibitors”, read by our …›Nov 18 · Rule based · BackgroundBackgroundPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · BackgroundNov 16 · Claude Opus 5.5 · Background · optionBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

Made here2 judgments on this link
NCT06802757gives it, found by reading the recordPembrolizumabDefined by Claude Opus 5.5Nov 1, 2026, 8:22 AM UTC
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background · option
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Pembrolizumabmade hereClaude Opus 5.5BackgroundReplaced
Nov 4The record itselfClinicalTrials.gov recordVersion of 2026-11-04Record change
Nov 4The record itselfRule based · nightly checkReading set asideCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16Pembrolizumabmade hereClaude Opus 5.5Background · optionCurrent
Nov 18PosaconazoleRule based · role ruleTestedCurrent
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundCurrent
Nov 18CarboplatinRule based · role ruleBackgroundCurrent
Nov 18AnthracyclinesRule based · role ruleBackgroundCurrent
Nov 18CyclophosphamideRule based · role ruleBackgroundCurrent
Nov 18Immune checkpoint inhibitorsRule based · role ruleBackgroundCurrent
As of nowTriple Negative Breast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.